Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data
Showed Superior Diabetes Risk-Benefit From Higher Ozempic Dose
Reductions in blood glucose seen in the SUSTAIN FORTE study using a higher dose of Ozempic may help type 2 diabetes patients further improve their diabetes control, with comparable tolerability to currently approved Ozempic 1.0 mg.
You may also be interested in...
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.